GLP-1R Agonist Treatment for Opioid Use Disorder
Phase 2
200
about 1.9 years
18–75
3 sites in MD, NY, PA
What this study is about
Researchers are testing if semaglutide, a medication, can reduce opioid use in adults receiving treatment for opioid use disorder. The trial will compare semaglutide to a placebo (a needle prick with no drug) over 686 days to see if semaglutide helps people refrain from using illicit and nonprescribed opioids.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Placebo
- 2.Take Semaglutide Pen Injector
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
antidiabetic (GLP-1 agonist; stimulates insulin release)
oral (Oral Tablet)
Psychiatry / Mental Health